武远众

职称：博士、副研究员、硕士生导师
专长：蛋白翻译后修饰与稳态调控
招生专业：分子医学
Email:  wuyzh@sysucc.org.cn

成果介绍：
　　蛋白翻译后修饰及稳态异常可引起细胞周期失调、表观遗传紊乱，导致肿瘤发生发展。围绕该科学问题开展系列原创性研究，开发了2个研究工具：蛋白稳定性调控因子筛选系统ProSRSA（Protein Stability Regulators Screening Assay）、内含子标记辅助基因敲入系统GEIS（Gene Editing through an Intronic Selection marker）。取得如下科学发现：（1）揭示乙酰转移酶KAT8与转录因子IRF1发生相分离，KAT8同时催化IRF1 K78、H4K16乙酰化以激活PD-L1转录，并研发阻断KAT8-IRF1相分离的抗肿瘤多肽；（2）系统性阐明乙酰化、SUMO化修饰可增强单链DNA结合蛋白hSSB1的蛋白稳态，进而稳定p53激活细胞周期检查点及促进DNA损伤修复，为hSSB1作为肿瘤放化疗增敏新靶点提供了实验证据；（3）揭示细胞周期检查点激酶Chk1/2磷酸化RBM28促进其核仁至核浆转位，核浆RBM28可多价结合p53抑制其转录活性，建立核仁应激与细胞周期串话机制，拓展了Chk1/2抑制剂临床应用。相关研究成果以通讯/第一作者（含共同）发表于Nat Cancer， Nat Commun， Nucleic Acids Res， Cell Res， Cell Discov， J Biol Chem， Cell Mol Life Sci，Signal Transduct Target Ther， Oncogene等高水平期刊。获授权专利2项，主持国家自然科学基金面上项目2项，受邀为中国科学院生物化学与生物物理学报撰写综述（封面发表），受邀在2019年全国肿瘤细胞生物学年会作学术报告。

教育背景和工作经历：
2021/02-至今，中山大学，肿瘤防治中心，副研究员
2015/08-2021/02，中山大学，肿瘤防治中心，助理研究员
2010/09–2015/07，中山大学，分子医学，博士，导师：康铁邦 
2006/09–2010/07，中山大学，生物技术，学士

代表性论文：
(1)Yuanzhong Wu #, Liwen Zhou #, Yezi Zou, Yijun Zhang, Meifang Zhang, Liping Xu, Lisi Zheng, Wenting He, Kuai Yu, Ting Li, Xia Zhang, Zhenxuan Chen, Ruhua Zhang, Penghu i Zhou, Nu Zhang, Limin Zheng, and Tiebang Kang *；Disrupting KAT8-IRF1 condensates diminishes PD-L1 expression and promotes antitumor immunity，Nature Cancer, 2023 Mar;4(3):382-400
(2)Lin, Xin#; Zhou, Liwen#; Zhong, Jianliang; Zhong, Li; Zhang, Ruhua; Kang, Tiebang*; Yuanzhong Wu*；RNA-binding protein RBM28 can translocate from the nucleolus to the nucleoplasm to inhibitthe transcriptional activity of p53., Journal of Biological Chemistry, 2022 Feb;298(2):101524. 
(3)Wang, Shang#; Li, Yuqing#; Zhong, Li#; Wu, Kai; Zhang, Ruhua; Kang, Tiebang; Wu, Song*; Yuanzhong Wu*；Efficient gene editing through an intronic selection marker in cells., Cellular and Molecular Life Sciences, 2022 Jan 31;79(2):111
(4)Xin Wang#, Ge Qin#, Xiaoting Liang, Wen Wang, Zhuo Wang, Dan Liao, Li Zhong, Ruhua Zhang, Yi-Xin Zeng, Yuanzhong Wu*，Tiebang Kang*. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma. Nature Communications，28 Feb 2020，volume 11, Article number: 1141.
(5)Liwen Zhou#, Lisi Zheng#, Kaishun Hu#, Xin Wang, Ruhua Zhang, Yezi Zou, Li Zhong, Shang Wang, Yuanzhong Wu*，Tiebang Kang*. SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites. Signal Transduction and Targeted Therapy. 2020 Jun 24;5(1):80. 
(6)Yuanzhong Wu#, Liwen Zhou#, Zifeng Wang, Xin Wang, Ruhua Zhang, Lisi Zheng, Tiebang Kang*. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library. Cancer Biol Med. 2020 Aug 15;17(3):782-794.
(7)Yuanzhong Wu, Liwen Zhou, Xin Wang, Jinping Lu, Ruhua Zhang, Xiaoting Liang, Li Wang, Wuguo Deng, Yi-xin Zeng, Tiebang Kang*. A genome-scale CRISPR-Cas9 screening method for protein stability reveals novel regulators of Cdc25A. Cell Discovery. 2016 May 24;2:16014. 
(8)Yuanzhong Wu#, Hongxia Chen#, Jinping Lu, Meifang Zhang, Ruhua Zhang, Tingmei Duan, Xin Wang, Jun Huang*, Tiebang Kang*. Acetylation dependent function of human single-strand DNA binding proteins 1. Nucleic Acids Research. 2015 Sep 18;43(16):7878-87. 
(9)Yuanzhong Wu, Jinping Lu, Tiebang Kang. Human single-stranded DNA binding proteins: guardians of genome stability. Acta Biochim Biophys Sin. 2016 Jul; 48(7):671-7 
(10)Shuangbing Xu#, Yuanzhong Wu#, Qiong Chen, Jingying Cao, Kaishun Hu, Jianjun Tang, Yi Sang, Fenju Lai, Li Wang, Ruhua Zhang, Sheng ping Li, Yixin Zeng, Yuxin Yin, Tiebang Kang*. hSSB1 regulates both the stability and the transcriptional activity of p53. Cell Research. 2013 Mar;23(3):423-35. 

专利：
（1）一种用于抑制细胞PD-L1表达的多肽及其应用，ZL201910185978.2，2021-1-1授权
（2）一种CRISPR-Cas9介导的外显子定点突变技术在细胞系中应用，ZL201910302026.4，2021-3-30授权
（3）基于CRISPR-dCas9的基因靶向去甲基化方法及其应用，2022106396990，实质性审查
 

更新时间：2023年4月17日